New Dental Warning for Buprenorphine.

Area of Science:

• Pharmacology
• Dental Medicine
• Public Health

Background:

• Transmucosal buprenorphine is a common treatment for opioid use disorder.
• Recent findings indicate a link between buprenorphine use and adverse dental outcomes.
• Updated drug labeling is necessary to inform patients and healthcare providers.

Purpose of the Study:

• To communicate updated safety information regarding transmucosal buprenorphine products.
• To highlight the risk of serious dental problems associated with buprenorphine treatment.
• To provide guidance for healthcare professionals on patient management.

Main Methods:

• Review of adverse event reports and clinical data.
• Update of the prescribing information for transmucosal buprenorphine formulations.
• Dissemination of new labeling requirements to healthcare providers.

Main Results:

• New warnings added to transmucosal buprenorphine labeling.
• Identified dental risks include tooth decay, cavities, oral infections, and tooth loss.
• Recommendations for oral health monitoring and patient education are emphasized.

Conclusions:

• Healthcare providers, including nurses and nurse practitioners (NPs), must perform oral assessments before initiating buprenorphine treatment.
• Patients need to be informed about potential dental side effects.
• Encouraging regular dental check-ups is crucial for patients on transmucosal buprenorphine therapy.